Market research
473A.F Adaptimmune Therapeutics plc
F EUR Not available
Latest close
As of 16 Nov 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 43M
- P/E ratio
- Not available
- Analyst target
- 9.83
- Dividend yield
- Not available
- Beta
- 2.41
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 43M
- P/E ratio
- Not available
- Analyst target
- 9.83
- Dividend yield
- Not available
- Beta
- 2.41
About
About Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Research context
Adaptimmune Therapeutics plc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 473A.F discussion.
5 years, 7 months ago
Adaptimmune Therapeutics plc is currently in a long term downtrend where the price is trading 25.5% below its 200 day moving average.
From a valuation standpoint, the stock is 85.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 196.7.
Adaptimmune Therapeutics plc's total revenue rose by 106.3% to $2M since the same quarter in the previous year.
Its net income has dropped by 24.7% to $-37M since the same quarter in the previous year.
Finally, its free cash flow fell by 131.2% to $-30M since the same quarter in the previous year.
Based on the above factors, Adaptimmune Therapeutics plc gets an overall score of 2/5.